I watched the conference and it appears they have a chance of becoming a profitable biotech company.
The pipeline is quite robust, imo. Their approach of activating the T Cells stands to make their platform for vaccines be very valuable and very successful, if they can commercialize and develop their pipeline. All my opinion of course.
News 
Market Data 
Discover 
